Search Prime Grants

W58P052220010

Cooperative Agreement

Overview

Grant Description
Covid-19 action. Ca for IBX (Ribonucleotide triphosphates (NTPs)).
Awardee
Trilink Biotechnologies
Grant Program (CFDA)
12.360 - Research on Chemical and Biological Defense
Awarding Agency
ACC Aberdeen Proving Ground (APG) [DoD - USA - AMC - ACC]
Funding Agency
Joint PEO for Chemical, Biological, Radiological and Nuclear Defense (JPEOCRBND) [DoD - USA - USAASC]
Place of Performance
San Diego, California 921215801 United States
Geographic Scope
Single Zip Code
Related Opportunity
None
Analysis Notes
Amendment Since initial award the total obligations have decreased 27% from $38,819,837 to $28,153,323.
Trilink Biotechnologies was awarded IBX for Covid-19: NTPs Treatment Cooperative Agreement W58P052220010 worth $28,153,323 from Joint PEO for Chemical, Biological, Radiological and Nuclear Defense in May 2022 with work to be completed primarily in California United States. The grant has a duration of 11 years 8 months and was awarded through assistance program 12.360 Research on Chemical and Biological Defense.

Status
(Ongoing)

Last Modified 5/25/23

Period of Performance
5/16/22
Start Date
1/1/34
End Date
28.0% Complete

Funding Split
$28.2M
Federal Obligation
$0.0
Non-Federal Obligation
$28.2M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to W58P052220010

Transaction History

Modifications to W58P052220010

Additional Detail

Award ID FAIN
W58P052220010
SAI Number
None
Award ID URI
None
Awardee Classifications
For-Profit Organization (Other Than Small Business)
Other
Awarding Office
W58P05 W6QK ACC-APG NATICK
Funding Office
W56XNH W6DZ JPMO CBD JPMO MCS (06)
Awardee UEI
JTZNJ1K5HUA4
Awardee CAGE
3Y9Z9
Performance District
51
Senators
Dianne Feinstein
Alejandro Padilla
Representative
Sara Jacobs
Modified: 5/25/23